CONTACT FORM

SCIENCE IN ACTION | Raanan Margalit, CEO | +972-52-3400426 | raanan.margalit@gmail.com

3 Pinchas Sapir St., Weizmann Science Park Ness Ziona, ISRAEL

Site Design: Ruth Kenan

Philanthropic DMD research

SIA performs philanthropic research in an effort to develop a cure for Duchenne Muscular Dystrophy (DMD). This is a collaboration with Israeli Duchenne Parent Association, Art Biosciences companies and other collaborators. SIA contributes experimental know how and conducts extensive research in DMD animal models. For more information on DMD research and collaboration options, please Contact Us at

raanan.margalit@gmail.com or at 972-52-3400426.

DMD is a devastating rare disease with substantial unmet need. DMD is the most common fatal genetic disorder diagnosed in childhood, affecting approximately 1 in every 3,500 live infants born. Because the Duchenne gene is located on the X-chromosome, it primarily affects boys; however, it occurs across all races and cultures. Duchenne results in progressive loss of strength and is caused by a mutation in the dystrophin encoding gene. Absence of dystrophin leads to a situation where muscle cells are easily damaged. The progressive muscle weakness leads to severe medical problems, particularly conditions relating to the heart and lungs.  Young men with Duchenne typically live into their late twenties.

SIA is strongly oriented to promote the research efforts to cure DMD. As a philanthropic initiative, SIA conducts collaborative research on several transgenic DMD mouse models and implementing various research approaches such as gene therapy, stem cells and anti-inflammatory therapy.

Philanthropic research in collaboration with Pluristem Therapeutics in Duchenne Muscular Dystrophy animal models led to promising results. (News Article)